Home » Stocks » Agile Therapeutics

Agile Therapeutics, Inc. (AGRX)

Stock Price: $2.63 USD -0.08 (-2.78%)
Updated Aug 5, 2020 10:00 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 228.93M
Revenue (ttm) n/a
Net Income (ttm) -21.82M
Shares Out 87.21M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 5, 2020
Last Price $2.63
Previous Close $2.70
Change ($) -0.08
Change (%) -2.78%
Day's Open 2.70
Day's Range 2.60 - 2.70
Day's Volume 276,139
52-Week Range 0.35 - 4.77

More Stats

Market Cap 228.93M
Enterprise Value 150.48M
Earnings Date (est) Aug 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 87.21M
Float 65.50M
EPS (basic) -0.36
EPS (diluted) -0.37
FCF / Share -0.25
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.69M
Short Ratio 2.14
Short % of Float 6.38%
Beta 1.47
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.41
Revenue n/a
Operating Income -21.77M
Net Income -21.82M
Free Cash Flow -18.87M
Net Cash 78.45M
Net Cash / Share 0.90
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -20.15%
ROE -37.86%
ROIC -131.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$7.20*
(174.29% upside)
Low
6.00
Current: $2.63
High
8.00
Target: 7.20
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue--------
Operating Income-18.86-19.54-26.81-29.72-33.09-18.52-12.73-23.32
Net Income-18.61-19.78-28.30-28.74-30.34-16.08-14.32-23.26
Shares Outstanding49.4334.3230.9428.2722.0211.390.050.04
Earnings Per Share-0.38-0.58-0.91-1.02-1.38-1.41-289.39-603.78
Operating Cash Flow-15.69-16.90-24.56-23.30-25.48-14.50-13.02-22.97
Capital Expenditures-0.10-0.32-1.31-0.03-0.29-0.10-4.95-6.69
Free Cash Flow-15.79-17.21-25.87-23.33-25.77-14.60-17.96-29.66
Cash & Equivalents34.487.8535.9548.7534.4040.182.120.00
Total Debt--10.6115.7115.2314.8314.87-
Net Cash / Debt34.487.8525.3533.0419.1625.35-12.760.00
Assets49.5422.3950.6063.8750.4254.8314.41-
Liabilities3.802.2214.2721.5820.6818.8285.85-
Book Value45.7520.1736.3242.2929.7436.01-71.44-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Agile Therapeutics, Inc.
Country United States
Employees 15
CEO Alfred F. Altomari

Stock Information

Ticker Symbol AGRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: AGRX
IPO Date May 23, 2014

Description

Agile Therapeutics, Inc., a women's healthcare company, focuses on the research, development, and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter and lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.